Live
Home·Deals·Biotechnology·AstraZeneca acquires CSPC
AstraZeneca acquires CSPC (2026)
SEO URLwww.firestrike.ai/deals/cspc-astrazeneca-acquisition-2026
acquisitionAnnounced · Feb 2, 2026BiotechnologySource · CredibleArticle · Factual
CSPC
AstraZeneca
CSPC · AstraZeneca

AstraZeneca acquires CSPC

David Najork
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
ShareXLinkedInEmail
Deal value
$1.2B
Target
CSPC
CSPC
Acquirer
AstraZeneca
AstraZeneca
Full Acquisition
Status
Pending

AstraZeneca agreed to acquire CSPC. Reported deal value: $1.2B. Status: Pending. Sector: Biotechnology. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-02-02. Figures and status may change as filings and press coverage update.

For the deal , AstraZeneca will make an upfront payment of $1.2 billion to CSPC , with the latter eligible to receive development and regulatory-based milestone payments of up to $3.5 billion across all eight programs

Deal timeline

Announced
Feb 2, 2026 · nasdaq.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context

This transaction is classified in Biotechnology with a reported deal value of $1.2B. Figures and status may change as sources update.

Sources: nasdaq.com · Primary article · FireStrike proprietary index